Vimarsana
Biggest News Aggregation in the World

Page 24 - Medication Guide News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Medication Guide. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Medication Guide Today - Breaking & Trending Today

GALDERMA AND NATIONAL BREAST CANCER FOUNDATION HONOR BREAST CANCER SURVIVORS AND THEIR BIGGEST CHAMPIONS IN THE "FACING BREAST CANCER TOGETHER" CAMPAIGN - Vimarsana News

GALDERMA AND NATIONAL BREAST CANCER FOUNDATION HONOR BREAST CANCER SURVIVORS AND THEIR BIGGEST CHAMPIONS IN THE "FACING BREAST CANCER TOGETHER" CAMPAIGN

/PRNewswire/ -- Galderma, the emerging pure-play dermatology category leader, today announced a new campaign to provide education and support for breast cancer...

FDA Releases Draft Labeling Guidance For Biosimilar Products - Life Sciences, Biotechnology & Nanotechnology - Vimarsana News

FDA Releases Draft Labeling Guidance For Biosimilar Products - Life Sciences, Biotechnology & Nanotechnology

Last week, FDA released a draft guidance, "Labeling for Biosimilar and Interchangeable Biosimilar Products" ("2023 Draft Guidance") that—when finalized—will revise and replace its July 2018...

Source: mondaq.com
Is It Biosimilar Or Interchangeable? It Won't Be Easy To Tell Under FDA's Latest Draft Labeling Guidance - Life Sciences, Biotechnology & Nanotechnology - Vimarsana News

Is It Biosimilar Or Interchangeable? It Won't Be Easy To Tell Under FDA's Latest Draft Labeling Guidance - Life Sciences, Biotechnology & Nanotechnology

Last week, FDA released a draft guidance, "Labeling for Biosimilar and Interchangeable Biosimilar Products" that—when finalized—will revise and replace its July 2018 final guidance...

Source: mondaq.com
Fabre-Kramer Pharmaceuticals Announces FDA Approval of EXXUA™, the First and Only Oral Selective 5HT1a Receptor Agonist for the Treatment of Major Depressive Disorder in Adults - Vimarsana News

Fabre-Kramer Pharmaceuticals Announces FDA Approval of EXXUA™, the First and Only Oral Selective 5HT1a Receptor Agonist for the Treatment of Major Depressive Disorder in Adults

/PRNewswire/ -- Fabre-Kramer Pharmaceuticals Inc. (Fabre-Kramer), a biopharmaceutical company committed to developing novel therapies to address unmet needs in...

Fabre-Kramer Pharmaceuticals Announces FDA Approval of EXXUAtm, the First and Only Oral Selective 5HT1a Receptor Agonist for the Treatment of Major Depressive Disorder in Adults - Vimarsana News

Fabre-Kramer Pharmaceuticals Announces FDA Approval of EXXUAtm, the First and Only Oral Selective 5HT1a Receptor Agonist for the Treatment of Major Depressive Disorder in Adults

Fabre-Kramer Pharmaceuticals Inc. (Fabre-Kramer), a biopharmaceutical company committed to developing novel therapies to address unmet needs in psychiatry and neurology, is pleased to announce that the U.S. Food and Drug Administration (FDA)...